{"id":"NCT00958009","sponsor":"EMD Serono","briefTitle":"The Multicenter, Open-label, Single-use Autoinjector Convenience Study","officialTitle":"A Twelve-week, Phase IIIb, Open-label, Single-arm, Multicenter Trial to Evaluate Ease of Use of a Ready-to-use, Single-use Autoinjector (SA) for Self-injection in Subjects With Relapsing Multiple Sclerosis (RMS) Treated With Rebif® 44mcg Subcutaneously (sc), Three Times a Week (Tiw)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2010-04","completion":"2010-06","firstPosted":"2009-08-13","resultsPosted":"2010-12-30","lastUpdate":"2013-08-07"},"enrollment":109,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":null},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DEVICE","name":"Rebidose®","otherNames":[]}],"arms":[],"summary":"The purpose of this trial is to test the Single-Use Autoinjector for a) ease of use; b) multiple domains related to subject's acceptability and satisfaction, and c) reliability of the correct function for self-injection of Rebif® 44 mcg sc tiw in subjects with relapsing multiple sclerosis (RMS).","primaryOutcome":{"measure":"Proportion of Relapsing Multiple Sclerosis (RMS) Subjects Rating the Single-use Autoinjector as 'Easy to Use' or 'Very Easy to Use' for Self-injection in a User Trial Questionnaire","timeFrame":"at 12 weeks","effectByArm":[{"arm":"RMS Subject Disposition","deltaMin":0.86,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":109},"commonTop":["Injection site erythema","Injection site pain","Influenza like illness","Injection site haematoma","Injection site swelling"]}}